Navigation Links
Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males
Date:4/22/2009

Feedback Can Influence New Product Development and Innovation

MOUNTAIN VIEW, Calif., April 22 /PRNewswire/ -- The latest end-user study from Frost & Sullivan's Pharmaceuticals & Biotechnology group assesses a variety of critical dynamics of drug delivery approaches and technologies in cancer treatment. Physicians, nurses and patients provided insight on factors such as perception, usage, reconstitution, home vs. office administration parameters, and barriers of leading drug delivery types, providing insight and feedback to cancer treatment developers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Selected findings from the survey include the following:

  • Nearly half of cancer patients surveyed wanted home infusion to last less than 1 hour.
  • Infusion nurses expected greater change in prescribing trends for cancer drug treatment over the next 12-24 months than oncologists.
  • Cancer patients were highly satisfied with implantable fusion pumps and oral delivery. While 75 percent of patients conduct drug delivery by themselves or a family member, oncologists and infusion nurses prefer this process be conducted by a trained healthcare worker or caregiver.
  • Oncologists and infusion nurses prefer oral as the leading type for new drug development, although other types were highly valued such as implants, transdermal patches, and implantable infusion pumps

Through more than 240 detailed interviews with medical oncologists, infusion nurses and cancer patients (breast, colorectal, lung, prostate) in the U.S., research analysts identified key insights into drug treatment, utilization, and potential future approaches to drug delivery in oncology.

From the Analyst
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards
2. Frost & Sullivan Applauds SHL Telemedicine for Excellence in Product Innovation
3. Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture
4. Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications
5. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
6. Frost & Sullivan Award Highlights Opportunity for Main Street Biotech
7. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
8. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
9. Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
10. Frost & Sullivan: In Vitro Diagnostics Market
11. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2012)... to voice concern on biosimilars pathways for patients with ... offered oral testimony at last week,s U.S. ... guidance of biosimilars products. IDF urged the FDA to ... order to protect the safety of patients with PIDD. ... an immune system that is either absent or hindered ...
(Date:5/16/2012)... May 16, 2012  UV Flu Technologies, ... to announce that it has signed a television ... San Bernardino Ca., for the filming of a ... "mini-infomercial." The commercial will run locally, regionally, and ... Comcast and Direct TV. The commercials will be ...
(Date:5/16/2012)... MAHWAH, N.J., May 16, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray ... a leading developer, manufacturer and marketer of medical ... L.P., (HealthTrust) is renewing its agreement for its ... With this agreement, Mindray provides monitoring that ... hospital departments and outpatient surgery centers for HealthTrust ...
(Date:5/15/2012)... Vermillion, Inc. (NASDAQ: VRML ), ... results for the first quarter ended March 31, 2012. ... In Q1, the volume of OVA1®, the company,s flagship ... ovarian masses, was generally in line with the forecast ... increase of 28% to 3,952 from the same year-ago ...
Breaking Biology Technology:Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway 2UV Flu Technologies to Commence a National TV Advertising Campaign 2UV Flu Technologies to Commence a National TV Advertising Campaign 3Mindray Renews Agreement with HealthTrust Purchasing Group, L.P. to Provide Patient Monitoring Equipment 2Vermillion Reports First Quarter 2012 Results 2Vermillion Reports First Quarter 2012 Results 3Vermillion Reports First Quarter 2012 Results 4Vermillion Reports First Quarter 2012 Results 5Vermillion Reports First Quarter 2012 Results 6Vermillion Reports First Quarter 2012 Results 7Vermillion Reports First Quarter 2012 Results 8
... Feb. 23 GeneraMedix, Inc. announced,today that it ... its improved,formulation of epoprostenol sodium for the intravenous ... a biopharmaceutical company with,its headquarters in Allschwil/Basel, Switzerland. ... "This sale speaks directly ...
... a developer of a pharmacogenomic test to identify potential ... Lilly and Company under the trademark Xigris (R)), announced ... at the annual Invest Northwest Investor-CEO forum conference on ... is presented by the Washington Biotechnology & Biomedical Association ...
... NEW YORK, Feb. 23 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... plans to release,fourth quarter and full year 2008 financial ... , The Company will hold ... 9, 2009 to,discuss fiscal fourth quarter and full year ...
Other Biology Technology:GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd. 2GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd. 3Sirius Genomics to Present at Invest Northwest Conference 2
(Date:5/20/2012)... May 2012. The Stem Cells and Cancer Research ... the Vall d,Hebrn Institute of Oncology (VHIO) has ... to certain drugs used in clinical trials for ... also benefited from the collaboration with Professor Alberto ... Alberto Sols, Consejo Superior de Investigaciones Cientficas (IIB-CSIC-Madrid). ...
(Date:5/18/2012)... /PRNewswire-iReach/ -- With chronic diseases continuing to ... and research to find "cures" continuing to take ... "a few years away," a small but growing ... the human consciousness. A number of healing practices ... geometry, and intention, have emerged, embracing practices first ...
(Date:5/18/2012)... McCauley and Paul DeSalles did not set out to ... documented. But that,s exactly what they and a team ... and faculty did in a new study published ... light on how human disturbance of the natural world ... ecological interaction chains. This, in turn, highlights the need ...
Breaking Biology News(10 mins):Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3Healing Method from Australia Addresses the Human Genome 2Stanford scientists document fragile land-sea ecological chain 2Vivakor Confirms Record Date of Stock Dividend 15068 1Vivakor Confirms Record Date of Stock Dividend 15068 2Vivakor Confirms Record Date of Stock Dividend 15068 3Amber Pharmacy Earns Accreditation From ACHC 6764 1Amber Pharmacy Earns Accreditation From ACHC 6764 2Cholesterol lowering drugs also may protect stem cell transplant patients from GVHD 62638 1Cholesterol lowering drugs also may protect stem cell transplant patients from GVHD 62638 2
... researchers led by the Smithsonian Institution has completed a ... the hobbit, a 3-foot-tall, 18,000-year-old hominin skeleton, discovered four ... study offers one of the most striking confirmations of ... remnant of one of the oldest human migrations to ...
... recently discovered that a chemical chain reaction that controls ... could mean the difference between normal growth and cancer. ... Cell, describes how organs can grow uncontrollably huge and ... , This chain reaction, a domino-like chain of events ...
... HONOLULU, Sept. 20 Women with low levels of vitamin ... a study led by the University of Pittsburgh Graduate School ... meeting of the American Society for Bone and Mineral Research ... professor of epidemiology, and colleagues evaluated patient data on 400 ...
Other Biology News:New research sheds light on 'Hobbit' 2Controlling for size may also prevent cancer 2Low vitamin D linked to higher risk of hip fracture 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Biology Products: